Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population

Saurabh Zanwar, Jithma Prasad Abeykoon, Prashant Kapoor

Research output: Contribution to journalReview article

Abstract

Purpose of Review: Approximately one half of the patient-population in multiple myeloma (MM) is > 70 years at diagnosis. Despite notable strides in the management and improved survival, MM remains incurable, with an increasing proportion of elderly patients comprising the relapsed-refractory cohort. Recent Findings: The arbitrary age cutoff at 65 years to define the elderly patient-population has evolved to a more nuanced categorization, incorporating a comprehensive assessment for determining frailty prior to commencing treatment. This step is critical in determining the therapy-intensity, including transplant-eligibility, to minimize toxicity. Dose-modifications are crucial, as the merits of continuous therapy are becoming evident in this patient-population. Bortezomib, lenalidomide, and dexamethasone (VRd) combination has emerged as standard of care for newly diagnosed MM. Fixed-duration Rd followed by reduced-dosed continuous R may be considered in select frail patients with standard-risk MM. Summary: Herein, we review the unique challenges encountered in elderly MM and discuss strategies for optimal management.

Original languageEnglish (US)
JournalCurrent Hematologic Malignancy Reports
DOIs
StatePublished - Jan 1 2019

Fingerprint

Multiple Myeloma
Population
Standard of Care
Dexamethasone
Therapeutics
Transplants
Survival

Keywords

  • Anti-myeloma therapy
  • Comorbidities
  • Frailty
  • Geriatric assessment
  • Supportive care
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. / Zanwar, Saurabh; Abeykoon, Jithma Prasad; Kapoor, Prashant.

In: Current Hematologic Malignancy Reports, 01.01.2019.

Research output: Contribution to journalReview article

@article{50166ea0e4c5479882df5fd97d9def8b,
title = "Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population",
abstract = "Purpose of Review: Approximately one half of the patient-population in multiple myeloma (MM) is > 70 years at diagnosis. Despite notable strides in the management and improved survival, MM remains incurable, with an increasing proportion of elderly patients comprising the relapsed-refractory cohort. Recent Findings: The arbitrary age cutoff at 65 years to define the elderly patient-population has evolved to a more nuanced categorization, incorporating a comprehensive assessment for determining frailty prior to commencing treatment. This step is critical in determining the therapy-intensity, including transplant-eligibility, to minimize toxicity. Dose-modifications are crucial, as the merits of continuous therapy are becoming evident in this patient-population. Bortezomib, lenalidomide, and dexamethasone (VRd) combination has emerged as standard of care for newly diagnosed MM. Fixed-duration Rd followed by reduced-dosed continuous R may be considered in select frail patients with standard-risk MM. Summary: Herein, we review the unique challenges encountered in elderly MM and discuss strategies for optimal management.",
keywords = "Anti-myeloma therapy, Comorbidities, Frailty, Geriatric assessment, Supportive care, Toxicity",
author = "Saurabh Zanwar and Abeykoon, {Jithma Prasad} and Prashant Kapoor",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11899-019-00500-4",
language = "English (US)",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population

AU - Zanwar, Saurabh

AU - Abeykoon, Jithma Prasad

AU - Kapoor, Prashant

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose of Review: Approximately one half of the patient-population in multiple myeloma (MM) is > 70 years at diagnosis. Despite notable strides in the management and improved survival, MM remains incurable, with an increasing proportion of elderly patients comprising the relapsed-refractory cohort. Recent Findings: The arbitrary age cutoff at 65 years to define the elderly patient-population has evolved to a more nuanced categorization, incorporating a comprehensive assessment for determining frailty prior to commencing treatment. This step is critical in determining the therapy-intensity, including transplant-eligibility, to minimize toxicity. Dose-modifications are crucial, as the merits of continuous therapy are becoming evident in this patient-population. Bortezomib, lenalidomide, and dexamethasone (VRd) combination has emerged as standard of care for newly diagnosed MM. Fixed-duration Rd followed by reduced-dosed continuous R may be considered in select frail patients with standard-risk MM. Summary: Herein, we review the unique challenges encountered in elderly MM and discuss strategies for optimal management.

AB - Purpose of Review: Approximately one half of the patient-population in multiple myeloma (MM) is > 70 years at diagnosis. Despite notable strides in the management and improved survival, MM remains incurable, with an increasing proportion of elderly patients comprising the relapsed-refractory cohort. Recent Findings: The arbitrary age cutoff at 65 years to define the elderly patient-population has evolved to a more nuanced categorization, incorporating a comprehensive assessment for determining frailty prior to commencing treatment. This step is critical in determining the therapy-intensity, including transplant-eligibility, to minimize toxicity. Dose-modifications are crucial, as the merits of continuous therapy are becoming evident in this patient-population. Bortezomib, lenalidomide, and dexamethasone (VRd) combination has emerged as standard of care for newly diagnosed MM. Fixed-duration Rd followed by reduced-dosed continuous R may be considered in select frail patients with standard-risk MM. Summary: Herein, we review the unique challenges encountered in elderly MM and discuss strategies for optimal management.

KW - Anti-myeloma therapy

KW - Comorbidities

KW - Frailty

KW - Geriatric assessment

KW - Supportive care

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85062621515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062621515&partnerID=8YFLogxK

U2 - 10.1007/s11899-019-00500-4

DO - 10.1007/s11899-019-00500-4

M3 - Review article

C2 - 30820879

AN - SCOPUS:85062621515

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

ER -